KRW 12270.0
(-2.54%)
Year | Total Assets | Total Assets Growth |
---|---|---|
2023 | 790.33 Billion KRW | -9.27% |
2022 | 871.1 Billion KRW | 3.51% |
2021 | 841.56 Billion KRW | 2.76% |
2020 | 818.92 Billion KRW | 9.38% |
2019 | 748.66 Billion KRW | 14.72% |
2018 | 652.61 Billion KRW | 2.08% |
2017 | 639.34 Billion KRW | 2.65% |
2016 | 622.84 Billion KRW | 17.39% |
2015 | 530.58 Billion KRW | 2.93% |
2014 | 515.48 Billion KRW | 8.86% |
2013 | 473.52 Billion KRW | 8.51% |
2012 | 436.39 Billion KRW | 6.9% |
2011 | 408.21 Billion KRW | 22.51% |
2010 | 333.22 Billion KRW | 4.53% |
2009 | 318.77 Billion KRW | 6.81% |
2008 | 298.46 Billion KRW | 2.47% |
2007 | 291.25 Billion KRW | 0.0% |
Year | Total Assets | Total Assets Growth |
---|---|---|
2024 Q1 | 811.11 Billion KRW | 2.63% |
2024 Q2 | 777.75 Billion KRW | -4.11% |
2023 Q4 | 790.33 Billion KRW | -5.24% |
2023 Q1 | 867.76 Billion KRW | -0.38% |
2023 Q3 | 834.05 Billion KRW | -1.13% |
2023 Q2 | 843.57 Billion KRW | -2.79% |
2023 FY | 790.33 Billion KRW | -9.27% |
2022 Q1 | 863.74 Billion KRW | 2.64% |
2022 Q2 | 821.28 Billion KRW | -4.92% |
2022 FY | 871.1 Billion KRW | 3.51% |
2022 Q4 | 871.1 Billion KRW | 0.06% |
2022 Q3 | 870.6 Billion KRW | 6.01% |
2021 Q2 | 908.34 Billion KRW | 9.24% |
2021 Q3 | 858.23 Billion KRW | -5.52% |
2021 FY | 841.56 Billion KRW | 2.76% |
2021 Q1 | 831.47 Billion KRW | 1.53% |
2021 Q4 | 841.56 Billion KRW | -1.94% |
2020 Q4 | 818.92 Billion KRW | -0.19% |
2020 FY | 818.92 Billion KRW | 9.38% |
2020 Q1 | 765.32 Billion KRW | 2.22% |
2020 Q3 | 820.49 Billion KRW | 0.43% |
2020 Q2 | 817.01 Billion KRW | 6.75% |
2019 Q2 | 675.45 Billion KRW | -0.55% |
2019 FY | 748.66 Billion KRW | 14.72% |
2019 Q4 | 748.66 Billion KRW | 4.44% |
2019 Q3 | 716.83 Billion KRW | 6.13% |
2019 Q1 | 679.21 Billion KRW | 4.08% |
2018 Q1 | 648.12 Billion KRW | 1.37% |
2018 Q4 | 652.61 Billion KRW | 0.61% |
2018 Q3 | 648.62 Billion KRW | -0.74% |
2018 FY | 652.61 Billion KRW | 2.08% |
2018 Q2 | 653.47 Billion KRW | 0.83% |
2017 Q2 | 623.42 Billion KRW | 0.15% |
2017 Q3 | 682.99 Billion KRW | 9.56% |
2017 Q4 | 639.34 Billion KRW | -6.39% |
2017 FY | 639.34 Billion KRW | 2.65% |
2017 Q1 | 622.46 Billion KRW | -0.06% |
2016 Q1 | 549.01 Billion KRW | 3.47% |
2016 Q3 | 573.68 Billion KRW | 0.73% |
2016 Q4 | 622.84 Billion KRW | 8.57% |
2016 FY | 622.84 Billion KRW | 17.39% |
2016 Q2 | 569.55 Billion KRW | 3.74% |
2015 FY | 530.58 Billion KRW | 2.93% |
2015 Q4 | 530.58 Billion KRW | 0.0% |
2014 Q1 | 533.09 Billion KRW | 12.58% |
2014 FY | 515.48 Billion KRW | 8.86% |
2014 Q2 | 525.58 Billion KRW | -1.41% |
2014 Q3 | 525.84 Billion KRW | 0.05% |
2013 Q1 | 449.27 Billion KRW | 2.95% |
2013 Q3 | 455.95 Billion KRW | 2.05% |
2013 Q4 | 473.52 Billion KRW | 3.85% |
2013 FY | 473.52 Billion KRW | 8.51% |
2013 Q2 | 446.78 Billion KRW | -0.55% |
2012 Q4 | 436.39 Billion KRW | 0.0% |
2012 FY | 436.39 Billion KRW | 6.9% |
2012 Q1 | 411.4 Billion KRW | 0.0% |
2011 FY | 408.21 Billion KRW | 22.51% |
2011 Q3 | 417.82 Billion KRW | 5.73% |
2011 Q2 | 395.16 Billion KRW | 1.59% |
2011 Q1 | 388.99 Billion KRW | 16.74% |
2010 Q4 | 333.22 Billion KRW | -9.28% |
2010 FY | 333.22 Billion KRW | 4.53% |
2010 Q2 | 351.1 Billion KRW | 8.97% |
2010 Q3 | 367.29 Billion KRW | 4.61% |
2010 Q1 | 322.21 Billion KRW | 1.08% |
2009 Q3 | 300.86 Billion KRW | 1.49% |
2009 Q2 | 296.45 Billion KRW | 0.79% |
2009 Q4 | 318.77 Billion KRW | 5.95% |
2009 Q1 | 294.12 Billion KRW | -1.45% |
2009 FY | 318.77 Billion KRW | 6.81% |
2008 Q2 | 292.65 Billion KRW | 2.09% |
2008 Q1 | 286.66 Billion KRW | -1.57% |
2008 Q3 | 295.62 Billion KRW | 1.01% |
2008 FY | 298.46 Billion KRW | 2.47% |
2008 Q4 | 298.46 Billion KRW | 0.96% |
2007 Q2 | 264.25 Billion KRW | 3.07% |
2007 Q1 | 256.37 Billion KRW | 0.0% |
2007 Q3 | 277.86 Billion KRW | 5.15% |
2007 FY | 291.25 Billion KRW | 0.0% |
2007 Q4 | 291.25 Billion KRW | 4.82% |
Name | Total Assets | Total Assets Difference |
---|---|---|
Yuyu Pharma, Inc. | 198.21 Billion KRW | -298.731% |
Dong-A Socio Holdings Co., Ltd. | 1957.1 Billion KRW | 59.617% |
Ildong Holdings Co., Ltd. | 876.99 Billion KRW | 9.881% |
Kukje Pharma Co., Ltd. | 170.61 Billion KRW | -363.217% |
Yuhan Corporation | 2814.07 Billion KRW | 71.915% |
Dong-A ST Co., Ltd. | 1315.21 Billion KRW | 39.908% |
SAMSUNG PHARM. Co., LTD. | 93.47 Billion KRW | -745.473% |
Hanmi Pharm. Co., Ltd. | 1952.03 Billion KRW | 59.512% |
Hanall Biopharma Co.,Ltd | 239.74 Billion KRW | -229.656% |
Ilyang Pharmaceutical Co.,Ltd | 468.9 Billion KRW | -68.551% |
Dong Sung Bio Pharm.Co.,Ltd. | 114.97 Billion KRW | -587.412% |
MYUNGMOON Pharm co.,Ltd | 236.54 Billion KRW | -234.113% |
Hana Pharm Co., Ltd. | 348.38 Billion KRW | -126.857% |
Yuyu Pharma, Inc. | 198.21 Billion KRW | -298.731% |
Ilsung Pharmaceuticals Co., Ltd. | 419.18 Billion KRW | -88.54% |
REYON Pharmaceutical Co., Ltd. | 499.77 Billion KRW | -58.139% |
Aprogen pharmaceuticals,Inc. | 589.39 Billion KRW | -34.093% |
JW Holdings Corporation | 1176.26 Billion KRW | 32.809% |
Ildong Pharmaceutical Co., Ltd. | 611.26 Billion KRW | -29.297% |
Chong Kun Dang Pharmaceutical Corp. | 1402.42 Billion KRW | 43.645% |
JW Pharmaceutical Corporation | 645.03 Billion KRW | -22.526% |
Shin Poong Pharm.Co.,Ltd. | 350.08 Billion KRW | -125.757% |
Hyundai Pharmaceutical Co., Ltd. | 154.04 Billion KRW | -413.071% |
Samil Pharmaceutical Co.,Ltd | 370.68 Billion KRW | -113.213% |
Jeil Pharmaceutical Co.,Ltd | 487.32 Billion KRW | -62.179% |
Yuyu Pharma, Inc. | 198.21 Billion KRW | -298.731% |
Kwang Dong Pharmaceutical Co., Ltd. | 1078.06 Billion KRW | 26.689% |
Daewoong pharmaceutical Co.,Ltd | 1770.31 Billion KRW | 55.356% |
JW Pharmaceutical Corporation | 645.03 Billion KRW | -22.526% |
Yuhan Corporation | 2814.07 Billion KRW | 71.915% |
Jeil Pharma Holdings Inc | 879.99 Billion KRW | 10.188% |
Yungjin Pharm. Co., Ltd. | 226.6 Billion KRW | -248.781% |
Suheung Co., Ltd. | 993.73 Billion KRW | 20.468% |
JW Pharmaceutical Corporation | 645.03 Billion KRW | -22.526% |
Samjin Pharmaceuticals Co., Ltd. | 419.9 Billion KRW | -88.22% |
Korea United Pharm Inc. | 468.86 Billion KRW | -68.566% |
CKD Bio Corp. | 293.78 Billion KRW | -169.02% |
Daewon Pharmaceutical Co., Ltd. | 507.99 Billion KRW | -55.579% |
Dongwha Pharm.Co.,Ltd | 564.97 Billion KRW | -39.89% |
Whan In Pharm Co.,Ltd. | 401.22 Billion KRW | -96.981% |
Shin Poong Pharm.Co.,Ltd. | 350.08 Billion KRW | -125.757% |
Chong Kun Dang Holdings Corp. | 1456 Billion KRW | 45.719% |
Boryung Corporation | 922.36 Billion KRW | 14.313% |
Bukwang Pharmaceutical Co., Ltd. | 442.46 Billion KRW | -78.623% |
Ilyang Pharmaceutical Co.,Ltd | 468.9 Billion KRW | -68.551% |
JW Lifescience Corporation | 255.83 Billion KRW | -208.924% |